Aimfinity Investment Corp. I Announces Approval by Shareholders of its Business Combination with Docter Inc.
Aimfinity Investment Corp. I (AIMAU) announced that shareholders have approved its business combination with Docter Inc., a Taiwanese health technology company, at an extraordinary general meeting on March 27, 2025. The approval was significant, with 93.8% of votes cast in favor of the combination.
Additionally, to extend the business combination completion deadline from March 28, 2025 to April 28, 2025, the sponsor's manager I-Fa Chang deposited $55,823.80 ($0.05 per Class A ordinary share) into AIMA's trust account. This marks the third of nine possible monthly extensions available under AIMA's current charter, which allows extensions from January 28, 2025 until October 28, 2025.
Aimfinity Investment Corp. I (AIMAU) ha annunciato che gli azionisti hanno approvato la sua fusione con Docter Inc., un'azienda taiwanese nel settore della tecnologia sanitaria, durante un'assemblea generale straordinaria tenutasi il 27 marzo 2025. L'approvazione è stata significativa, con il 93,8% dei voti espressi a favore della fusione.
Inoltre, per estendere la scadenza per il completamento della fusione dal 28 marzo 2025 al 28 aprile 2025, il manager dello sponsor I-Fa Chang ha depositato $55,823.80 ($0.05 per azione ordinaria di Classe A) nel conto fiduciario di AIMA. Questo segna la terza di nove possibili estensioni mensili disponibili secondo lo statuto attuale di AIMA, che consente estensioni dal 28 gennaio 2025 fino al 28 ottobre 2025.
Aimfinity Investment Corp. I (AIMAU) anunció que los accionistas han aprobado su fusión con Docter Inc., una empresa taiwanesa de tecnología en salud, en una reunión general extraordinaria el 27 de marzo de 2025. La aprobación fue significativa, con el 93.8% de los votos emitidos a favor de la fusión.
Además, para extender la fecha límite de finalización de la fusión del 28 de marzo de 2025 al 28 de abril de 2025, el gerente del patrocinador I-Fa Chang depositó $55,823.80 ($0.05 por acción ordinaria de Clase A) en la cuenta fiduciaria de AIMA. Esto marca la tercera de nueve posibles extensiones mensuales disponibles bajo el estatuto actual de AIMA, que permite extensiones desde el 28 de enero de 2025 hasta el 28 de octubre de 2025.
Aimfinity Investment Corp. I (AIMAU)는 주주들이 대만의 건강 기술 회사인 Docter Inc.와의 사업 결합을 2025년 3월 27일에 열린 특별 총회에서 승인했다고 발표했습니다. 이 승인은 결합에 찬성한 투표의 93.8%가 나오는 등 중요했습니다.
또한, 사업 결합 완료 기한을 2025년 3월 28일에서 2025년 4월 28일로 연장하기 위해 스폰서의 관리자 I-Fa Chang은 AIMA의 신탁 계좌에 $55,823.80 ($0.05 per Class A 보통주) 를 예치했습니다. 이는 AIMA의 현재 헌장에 따라 가능한 아홉 번의 월간 연장 중 세 번째를 나타내며, 2025년 1월 28일부터 2025년 10월 28일까지 연장을 허용합니다.
Aimfinity Investment Corp. I (AIMAU) a annoncé que les actionnaires ont approuvé sa fusion avec Docter Inc., une entreprise taïwanaise de technologie de la santé, lors d'une assemblée générale extraordinaire le 27 mars 2025. L'approbation a été significative, avec 93,8% des votes exprimés en faveur de la fusion.
De plus, pour prolonger la date limite d'achèvement de la fusion du 28 mars 2025 au 28 avril 2025, le gestionnaire du sponsor I-Fa Chang a déposé $55,823.80 ($0.05 par action ordinaire de Classe A) sur le compte fiduciaire d'AIMA. Cela marque la troisième des neuf extensions mensuelles possibles disponibles selon la charte actuelle d'AIMA, qui permet des extensions du 28 janvier 2025 au 28 octobre 2025.
Aimfinity Investment Corp. I (AIMAU) gab bekannt, dass die Aktionäre auf einer außerordentlichen Hauptversammlung am 27. März 2025 die Fusion mit Docter Inc., einem taiwanesischen Gesundheits-Technologieunternehmen, genehmigt haben. Die Genehmigung war signifikant, da 93,8% der abgegebenen Stimmen für die Fusion waren.
Darüber hinaus hat der Manager des Sponsors I-Fa Chang $55,823.80 ($0.05 pro Stammaktie der Klasse A) auf das Treuhandkonto von AIMA eingezahlt, um die Frist für den Abschluss der Fusion vom 28. März 2025 auf den 28. April 2025 zu verlängern. Dies stellt die dritte von neun möglichen monatlichen Verlängerungen dar, die gemäß der aktuellen Satzung von AIMA verfügbar sind und von 28. Januar 2025 bis 28. Oktober 2025 verlängert werden können.
- Strong shareholder support with 93.8% approval for the business combination
- Successfully secured third monthly extension, maintaining deal momentum
- Required additional time extension and capital contribution to complete the business combination
- Monthly extension payments of $0.05 per share reducing available capital
Wilmington, DE, March 28, 2025 (GLOBE NEWSWIRE) -- Aimfinity Investment Corp. I (the “AIMA”) (Nasdaq: AIMAU), a special purpose acquisition company, today announced that, the previously announced business combination (the "Business Combination") between AIMA and Docter Inc. (“Docter”), a Taiwanese health technology company, was approved at an extraordinary general meeting of shareholders (the "EGM") of AIMA on March 27, 2025. Approximately
In addition, in order to extend the date by which AIMA must complete the Business Combination from March 28, 2025 to April 28, 2025, on March 28, 2025, I-Fa Chang, manager of the sponsor of AIMA, deposited into AIMA’s trust account (the “Trust Account”) an aggregate of
Pursuant to AIMA’s fourth amended and restated memorandum and articles of association (“Current Charter”), effective January 9, 2025, AIMA may extend the date by which AIMA must complete the Business Combination on a monthly basis from January 28, 2025 until October 28, 2025 or such earlier date as may be determined by its board of directors by depositing the Monthly Extension Payment for each month into the Trust Account. This is the third of nine monthly extensions available under the Current Charter of AIMA.
About Aimfinity Investment Corp. I
Aimfinity Investment Corp. I is a special purpose acquisition company (SPAC) focused on merging with high-growth potential businesses and facilitating their entry into the capital markets.
About Docter Inc.
Docter Inc. is a leading health technology company dedicated to developing innovative health monitoring solutions that enhance the accessibility and efficiency of global healthcare services.
Additional Information and Where to Find It
As previously disclosed, on October 13, 2023, AIMA entered into that certain Agreement and Plan of Merger (as may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and between AIMA, Docter, Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and wholly-owned subsidiary of AIMA (“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of Purchaser (“Merger Sub”), pursuant to which AIMA is proposing to enter into a business combination with Docter involving an reincorporation merger and an acquisition merger. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. AIMA’s shareholders and other interested persons are advised to read, when available, the proxy statement/prospectus and the amendments thereto and other documents filed in connection with the proposed business combination, as these materials will contain important information about AIMA, Purchaser or Docter, and the proposed business combination. The proxy statement/prospectus and other relevant materials for the proposed business combination have been mailed to shareholders of AIMA as of the record date of February 25, 2025, established for voting on the proposed business combination. Such shareholders will also be able to obtain copies of the proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to AIMA’s principal office at 221 W 9th St, PMB 235 Wilmington, Delaware 19801.
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about the proposed transactions described herein, and the parties’ perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transaction, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the proposed transactions. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.
Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the proposed business combination, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the businesses; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iv) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of AIMA or Docter; (v) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of AIMA’s securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Docter to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (viii) risks relating to the medical device industry, including but not limited to governmental regulatory and enforcement changes, market competitions, competitive product and pricing activity; and (ix) risks relating to the combined company’s ability to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationship with its business partners.
A further list and description of risks and uncertainties can be found in the prospectus filed with the Securities and Exchange Commission (the “SEC”) on April 26, 2022 relating to AIMA’s initial public offering (File No. 333-263874), the annual report of AIMA on Form 10-K for the fiscal year ended on December 31, 2023, filed with the SEC on July 29, 2024, and in the final prospectus/proxy statement filed with the SEC on March 6, 2025 relating to the proposed transactions (File No. 333-284658) (the “Final Prospectus”), and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and AIMA, Docter, and their subsidiaries or affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
Additional Information and Where to Find It
In connection with the proposed transactions described herein, Purchaser filed the Final Prospectus with the SEC on March 6, 2025. The proxy statement and a proxy card will be mailed to AIMA’s shareholders of record as of February 25, 2025. Shareholders of AIMA will also be able to obtain a copy of the Final Prospectus without charge from AIMA. The Final Prospectus may also be obtained without charge at the SEC’s website at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF AIMA ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTIONS THAT AIMA WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AIMA, DOCTER AND THE PROPOSED TRANSACTIONS.
Participants in the Solicitation
AIMA, Docter, and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of AIMA’s shareholders in connection with the proposed transactions described herein. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of AIMA’s shareholders in connection with the proposed business combination is set forth in the Final Prospectus.
No Offer or Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of any potential transaction and does not constitute an offer to sell or a solicitation of an offer to buy any securities of AIMA, Purchaser or Docter, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.
Contact Information:
Aimfinity Investment Corp. I
I-Fa Chang
Chief Executive Officer
221 W 9th St, PMB 235
Wilmington, Delaware 19801
ceo@aimfinityspac.com
FAQ
What percentage of shareholders approved AIMAU's business combination with Docter Inc.?
How much was deposited for AIMAU's March 2025 extension payment?
How many monthly extensions are available for AIMAU's business combination?
When is the new deadline for AIMAU to complete its business combination with Docter Inc.?
